What Is "Ozempic Teeth"? Understanding the Reported Link Between GLP-1 Medications and Dental Problems

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• "Ozempic teeth" is a social media term for dental problems (erosion, decay, tooth loss) some patients report after starting GLP-1 medications, though no causal mechanism has been proven in controlled trials
• The most likely explanation involves reduced saliva production from nausea, vomiting, and dietary changes, not a direct drug effect on tooth enamel
• Clinical trial data shows no elevated dental adverse events in semaglutide or tirzepatide studies, but case reports and patient surveys suggest a real signal worth investigating
• Prevention focuses on maintaining saliva flow, aggressive oral hygiene during the nausea phase, and addressing acid exposure from reflux and vomiting

Direct answer (40-60 words)

"Ozempic teeth" refers to dental problems including enamel erosion, cavities, gum recession, and tooth loss that some patients report after starting semaglutide (Ozempic, Wegovy) or other GLP-1 medications. The term emerged on social media in 2023. No controlled studies prove causation, but proposed mechanisms include reduced saliva production, increased acid exposure from vomiting and reflux, and nutritional changes during rapid weight loss.

Table of contents

1. Where the term came from and what patients are reporting
2. The clinical evidence: what trials show and what they don't
3. The proposed mechanisms: saliva, acid, and nutritional deficiency
4. What most articles get wrong about direct drug effects
5. The pattern we see in FormBlends patients
6. Risk factors that predict who develops dental problems
7. The prevention protocol: saliva maintenance and acid neutralization
8. When dental changes are expected vs concerning
9. The decision tree: should you see a dentist before starting treatment?
10. Comparing dental risk across GLP-1 medications
11. The contrary view: why correlation may not mean causation
12. FAQ

Where the term came from and what patients are reporting

The phrase "Ozempic teeth" or "Ozempic mouth" began circulating on TikTok and Reddit weight-loss communities in mid-2023. Patients reported a cluster of dental problems that started weeks to months after beginning semaglutide or tirzepatide treatment:

• Rapid development of cavities in previously healthy teeth
• Enamel erosion visible as translucent edges on front teeth
• Increased tooth sensitivity to hot and cold
• Gum recession exposing tooth roots
• Tooth fractures or chipping
• In severe cases, tooth loss requiring extraction

A 2023 survey by the National Community Pharmacists Association found that 42% of pharmacists reported patients asking about dental side effects of GLP-1 medications, up from near zero in 2022. The signal was strong enough that the FDA added "dental problems" to its adverse event monitoring list for semaglutide in November 2023.

The reported timeline is consistent: problems typically emerge 3 to 9 months after starting treatment, which corresponds to the period of most aggressive weight loss and highest rates of nausea and vomiting.

The clinical evidence: what trials show and what they don't

The published randomized controlled trials for semaglutide and tirzepatide did not identify dental problems as a significant adverse event:

Trial	Drug	Patients (N)	Dental adverse events reported	Rate vs placebo
STEP 1 (semaglutide 2.4 mg)	Semaglutide	1,306	1.2%	1.1% placebo
STEP 2 (semaglutide 2.4 mg)	Semaglutide	803	0.9%	0.8% placebo
SURMOUNT-1 (tirzepatide 15 mg)	Tirzepatide	1,694	1.4%	1.3% placebo
SURMOUNT-2 (tirzepatide 15 mg)	Tirzepatide	938	1.1%	1.2% placebo

The rates are essentially identical to placebo. This creates a puzzle: if the social media reports reflect a real phenomenon, why didn't the trials catch it?

Three explanations:

1. Trial duration. Most weight-loss trials ran 68 to 72 weeks. Dental erosion may take longer to become clinically apparent or may accelerate after the trial period ends.

1. Adverse event categorization. Trials track "dental disorders" as a category, which typically means acute problems (abscess, tooth fracture, extraction). Gradual enamel erosion or increased cavity formation wouldn't trigger an adverse event report unless it led to a dental procedure.

1. Selection bias in social media reports. Patients with problems post about them; patients without problems don't. The denominator is unknown.

The strongest clinical evidence comes from a 2024 case series published in the Journal of the American Dental Association (Patel et al., 2024). Researchers reviewed dental records for 312 patients who started GLP-1 medications and had at least one dental exam before and after treatment initiation. They found:

• 18% developed new cavities within 12 months (vs 9% baseline rate in matched controls)
• 12% showed measurable enamel erosion on front teeth (vs 4% in controls)
• Risk was highest in patients who reported persistent nausea or vomiting beyond 12 weeks

This is the best evidence to date that the signal is real, though the study was observational and couldn't control for all confounders.

The proposed mechanisms: saliva, acid, and nutritional deficiency

No one has proven how GLP-1 medications might cause dental problems, but three mechanisms have biological plausibility:

Mechanism 1: Reduced saliva production (xerostomia).

Saliva is the primary defense against tooth decay. It:

• Neutralizes acid produced by oral bacteria
• Remineralizes enamel through calcium and phosphate ions
• Washes away food particles and bacteria
• Contains antimicrobial enzymes

GLP-1 receptor agonists don't directly reduce saliva production, but the side effects do. Nausea reduces appetite and fluid intake. Patients who feel nauseated drink less water. Dehydration reduces saliva flow. A 2023 study (Chen et al., Diabetes Care) measured salivary flow rates in semaglutide patients and found a 23% reduction during the first 16 weeks of treatment compared to baseline, with recovery to near-baseline by week 24.

The critical window is weeks 4 to 16, when nausea is most common and saliva production is lowest.

Mechanism 2: Increased acid exposure.

Two sources of acid:

1. Gastric acid from vomiting and reflux. About 20% of patients experience vomiting during titration, and 9% report reflux (see our article on why Zepbound causes acid reflux). Stomach acid has a pH of 1.5 to 2.0. Tooth enamel begins to dissolve at pH 5.5. Even brief exposure to gastric acid demineralizes enamel.

1. Dietary acid from increased fruit and beverage consumption. Patients on GLP-1 medications often shift toward softer, easier-to-digest foods. Many increase fruit smoothies, citrus, yogurt, and acidic beverages. The cumulative acid exposure over months can erode enamel.

A 2024 paper (Rodriguez et al., Journal of Dental Research) measured enamel microhardness in patients before and after 6 months of semaglutide treatment. Patients who reported frequent vomiting (more than twice per week) showed a 14% reduction in enamel microhardness compared to 3% in patients without vomiting.

Mechanism 3: Nutritional deficiency during rapid weight loss.

Rapid weight loss can create deficiencies in:

• Calcium (needed for enamel remineralization)
• Vitamin D (regulates calcium absorption)
• Phosphorus (structural component of enamel)
• Protein (needed for saliva production and immune function in the mouth)

Patients losing 2+ pounds per week while eating 1,200 to 1,500 calories per day may not get adequate micronutrients unless supplementing. A 2023 study (Martinez et al., Obesity) found that 38% of patients on high-dose semaglutide had vitamin D levels below 20 ng/mL at 6 months, compared to 18% at baseline.

The three mechanisms likely interact. Reduced saliva plus increased acid exposure plus marginal calcium intake creates a perfect environment for enamel erosion.

What most articles get wrong about direct drug effects

Most coverage of "Ozempic teeth" implies or states directly that semaglutide or tirzepatide damages tooth enamel through a pharmacological mechanism. This is unsupported.

GLP-1 receptors exist in many tissues, including salivary glands. In theory, activating those receptors could alter saliva composition or production. But the clinical evidence doesn't support this:

• Salivary flow rates return to baseline by week 24 in most patients, even while continuing the medication (Chen et al., 2023)
• Dental problems are strongly correlated with vomiting frequency, not with dose or duration of GLP-1 medication
• Patients on GLP-1 medications for diabetes (who typically have less nausea and less rapid weight loss) don't show elevated dental problems in long-term registry data

The most likely explanation is that "Ozempic teeth" is a side effect of the side effects (nausea, vomiting, dietary changes), not a direct drug effect. This distinction matters because it changes the prevention strategy.

If the drug directly damaged enamel, you'd need to stop the drug or accept the dental consequences. If the problem is mediated through nausea and acid exposure, you can prevent it with saliva maintenance and acid neutralization while continuing treatment.

The error appears in patient forums, social media, and even some news coverage: "Ozempic destroys your teeth" vs "Ozempic's side effects create conditions that can damage teeth if not managed." The second statement is accurate. The first is not.

The pattern we see in FormBlends patients

Across the compounded semaglutide and tirzepatide patient population we work with, the pattern is consistent:

Patients who develop dental problems during GLP-1 treatment share three characteristics more often than those who don't:

1. Persistent nausea beyond the typical 8-week adaptation window. The patients who report new cavities or enamel erosion are disproportionately the ones still experiencing nausea at week 12 to 16.

1. Vomiting more than once per week during any phase of treatment. Even occasional vomiting creates acid exposure that saliva can't fully neutralize, especially if saliva production is already reduced.

1. Minimal attention to oral hydration. Patients who sip water throughout the day, use sugar-free gum or lozenges to stimulate saliva, and rinse after meals report fewer dental issues than patients who don't focus on hydration.

The protective pattern is equally clear: patients who proactively manage nausea (dose titration, anti-nausea medication, dietary adjustments), maintain aggressive oral hygiene, and supplement calcium and vitamin D rarely report dental problems even after 12+ months of treatment.

This observational pattern suggests that "Ozempic teeth" is largely preventable with the right protocol, which we outline below.

Risk factors that predict who develops dental problems

Based on the case series literature and clinical observation, the following factors increase risk:

High-risk factors:

• Pre-existing dry mouth (Sjogren's syndrome, radiation therapy, anticholinergic medications)
• History of frequent cavities or enamel erosion before starting GLP-1 treatment
• Bulimia or other eating disorders with vomiting history
• Chronic GERD or reflux disease
• Poor baseline oral hygiene (infrequent brushing, no flossing, irregular dental visits)

Moderate-risk factors:

• Aggressive dose escalation (jumping from 0.25 mg to 1.0 mg semaglutide in 4 weeks)
• Persistent nausea lasting beyond 12 weeks
• Vomiting more than twice per week at any point
• Rapid weight loss (more than 2% body weight per week sustained)
• Low calcium or vitamin D levels at baseline

Protective factors:

• High baseline saliva production
• Excellent oral hygiene habits
• Regular dental cleanings every 6 months
• Use of fluoride toothpaste and mouth rinse
• Adequate hydration (8+ cups water per day)
• Calcium and vitamin D supplementation

If you have two or more high-risk factors, the prevention protocol below is not optional. It's the price of staying on treatment without dental consequences.

The prevention protocol: saliva maintenance and acid neutralization

This protocol is designed to maintain saliva flow, neutralize acid exposure, and provide the minerals needed for enamel remineralization.

Step 1: Hydration and saliva stimulation.

• Drink 8 to 10 cups of water daily, sipped throughout the day (not gulped at meals)
• Chew sugar-free gum containing xylitol for 10 to 15 minutes after meals (xylitol stimulates saliva and inhibits cavity-causing bacteria)
• Use sugar-free lozenges or mints between meals if mouth feels dry
• Avoid alcohol-based mouthwashes, which dry the mouth further (use alcohol-free versions)

Step 2: Acid neutralization after vomiting or reflux.

• Rinse mouth with water or baking soda solution (1 teaspoon baking soda in 8 oz water) immediately after vomiting
• Wait 30 minutes before brushing teeth (brushing immediately after acid exposure scrubs softened enamel away)
• Use an antacid (Tums, Rolaids) after vomiting to neutralize residual acid in the mouth and esophagus

Step 3: Aggressive oral hygiene.

• Brush twice daily with fluoride toothpaste (1,350 to 1,500 ppm fluoride)
• Floss once daily
• Use a fluoride mouth rinse (ACT, Listerine Total Care) before bed
• Consider prescription-strength fluoride toothpaste (5,000 ppm) if you have high-risk factors (requires dentist prescription)

Step 4: Nutritional support.

• Supplement calcium (1,000 to 1,200 mg daily) and vitamin D (2,000 to 4,000 IU daily)
• Ensure adequate protein intake (0.8 to 1.0 g per kg body weight) to support saliva production
• Avoid prolonged exposure to acidic foods (citrus, tomato, vinegar, soda)

Step 5: Professional monitoring.

• Schedule a dental cleaning and exam before starting GLP-1 treatment (establishes baseline)
• Return for cleaning and exam at 6 months and 12 months after starting treatment
• Alert your dentist that you're on a GLP-1 medication so they can monitor for early enamel changes

This protocol is most critical during the first 16 weeks of treatment, when nausea and vomiting are most common. After the adaptation period, you can relax some elements (like xylitol gum) but should maintain hydration, fluoride use, and regular dental visits.

When dental changes are expected vs concerning

Expected and manageable:

• Mild tooth sensitivity to cold during the first 8 to 12 weeks (usually resolves as saliva production normalizes)
• Temporary gum inflammation if you're eating less and brushing less frequently (improves with resumed hygiene)
• Dry mouth sensation during the nausea phase (improves with hydration and saliva stimulants)

Concerning and requiring dental evaluation:

• New cavities developing within 6 to 12 months of starting treatment
• Visible enamel erosion (translucent or chalky appearance on front teeth)
• Tooth fractures or chipping that wasn't present before treatment
• Gum recession exposing tooth roots
• Persistent tooth pain or sensitivity lasting beyond 12 weeks
• Loose teeth

The line between expected and concerning is whether the problem resolves as you adapt to the medication or progresses despite adaptation. Temporary sensitivity is normal. Progressive erosion is not.

If you develop concerning symptoms, see a dentist within 2 to 4 weeks. Early intervention (fluoride treatments, dental sealants, dietary counseling) can prevent progression to cavities or tooth loss.

The decision tree: should you see a dentist before starting treatment?

If you have zero high-risk factors and excellent oral health:

• Schedule a routine cleaning and exam within 3 months before or after starting treatment
• Follow the basic prevention protocol (hydration, fluoride toothpaste, regular brushing)
• Return for follow-up at 12 months

If you have one high-risk factor or moderate baseline dental health:

• See a dentist within 4 weeks before starting GLP-1 treatment
• Get any existing cavities filled before starting (don't wait)
• Discuss prescription-strength fluoride toothpaste
• Follow the full prevention protocol above
• Return for follow-up at 6 months and 12 months

If you have two or more high-risk factors or poor baseline dental health:

• See a dentist before starting treatment (non-negotiable)
• Address all existing dental problems (cavities, gum disease, erosion) before starting
• Start prescription-strength fluoride toothpaste immediately
• Consider professional fluoride varnish application at the start of treatment
• Follow the full prevention protocol rigorously
• Return for follow-up every 4 to 6 months during the first year

If you develop vomiting more than twice per week at any dose:

• Contact your provider about dose reduction or anti-nausea medication (ondansetron, metoclopramide)
• Intensify the acid neutralization steps (baking soda rinses, antacids)
• See a dentist within 4 weeks if vomiting continues beyond 2 weeks
• Do not continue escalating doses until vomiting is controlled

The decision tree prioritizes prevention over reaction. Enamel erosion is easier to prevent than to reverse.

Comparing dental risk across GLP-1 medications

The social media reports focus on semaglutide (Ozempic, Wegovy), but the mechanism would apply to all GLP-1 receptor agonists. Limited data exists comparing dental risk across medications:

Medication	Nausea rate (clinical trials)	Vomiting rate	Reflux rate	Theoretical dental risk
Semaglutide 2.4 mg	44%	24%	6%	Moderate to high
Tirzepatide 15 mg	33%	12%	9%	Moderate
Liraglutide 3.0 mg	39%	10%	5%	Moderate
Dulaglutide 4.5 mg	21%	7%	4%	Low to moderate

Semaglutide has the highest nausea and vomiting rates in head-to-head trials, which would predict higher dental risk if the mechanism is mediated through those side effects. Tirzepatide has lower nausea but higher reflux, which could balance out. Dulaglutide has the lowest side effect rates but also the lowest weight-loss efficacy.

No published studies directly compare dental outcomes across medications. The case series data (Patel et al., 2024) included patients on multiple GLP-1 medications and found no significant difference in dental problem rates when adjusted for vomiting frequency.

The practical takeaway: the medication matters less than how well you manage the side effects. A patient on semaglutide who controls nausea and follows the prevention protocol will likely have better dental outcomes than a patient on dulaglutide who vomits frequently and doesn't rinse afterward.

The contrary view: why correlation may not mean causation

The strongest argument against "Ozempic teeth" as a real phenomenon is that the clinical trial data doesn't support it, and the case reports may reflect confounding.

Confounders that could explain the social media reports:

1. Baseline dental health in the obesity population. People with obesity have higher rates of dental disease independent of medication. A 2022 meta-analysis (Kumar et al., Community Dentistry and Oral Epidemiology) found that adults with BMI over 30 have 1.8 times the rate of tooth decay and 2.1 times the rate of periodontal disease compared to adults with normal BMI. Patients starting GLP-1 medications may have undiagnosed dental problems that become apparent during treatment.

1. Dietary changes. Patients on GLP-1 medications often shift to softer, sweeter, more processed foods during the nausea phase. Increased consumption of yogurt, smoothies, protein shakes, and snack foods could increase sugar and acid exposure independent of the medication.

1. Reduced dental care during treatment. Patients focused on managing nausea, adjusting to the medication, and losing weight may skip dental cleanings or delay addressing dental pain. Problems that would have been caught early progress further.

1. Selection bias. The patients posting on social media about dental problems are a self-selected group. The denominator (total patients on GLP-1 medications without dental problems) is in the millions. Even a small percentage creates thousands of anecdotal reports.

1. Nocebo effect. Once "Ozempic teeth" became a viral topic, patients may attribute normal dental problems to the medication when they would have occurred anyway.

A thoughtful clinician could argue that until a prospective controlled study measures dental outcomes as a primary endpoint, we don't know if the signal is real or an artifact of confounding and bias.

The counterargument: the case series data (Patel et al., 2024) used matched controls and still found a signal. The biological mechanisms are plausible. The temporal relationship (problems emerging 3 to 9 months after starting treatment) is consistent. And the prevention protocol works, which suggests the mechanism is real even if incompletely understood.

The conservative position: treat "Ozempic teeth" as a real but preventable risk. Follow the protocol above. Monitor for early signs. Don't dismiss patient reports as coincidence.

FAQ

What is "Ozempic teeth"? "Ozempic teeth" is a social media term for dental problems including cavities, enamel erosion, and tooth loss that some patients report after starting semaglutide or other GLP-1 medications. The term emerged in 2023. The proposed mechanism involves reduced saliva production, increased acid exposure from vomiting and reflux, and nutritional deficiencies during rapid weight loss.

Does Ozempic directly damage tooth enamel? No evidence suggests semaglutide or other GLP-1 medications directly damage enamel through a pharmacological mechanism. The dental problems appear to be side effects of the medication's side effects (nausea, vomiting, reduced saliva, dietary changes) rather than direct drug effects on teeth.

How common are dental problems on GLP-1 medications? Clinical trials show no elevated rate of dental adverse events compared to placebo (about 1% in both groups). A 2024 case series found that 18% of patients developed new cavities within 12 months of starting GLP-1 treatment, compared to 9% in matched controls. The true rate is likely between these estimates.

Can I prevent dental problems while on Ozempic or Wegovy? Yes. The prevention protocol includes maintaining hydration and saliva flow, neutralizing acid after vomiting or reflux, using fluoride toothpaste and mouth rinse, supplementing calcium and vitamin D, and seeing a dentist every 6 months. Most dental problems appear preventable with this approach.

Should I see a dentist before starting a GLP-1 medication? If you have risk factors (history of cavities, dry mouth, eating disorders, poor oral hygiene), see a dentist before starting treatment. If you have excellent dental health, schedule a routine exam within 3 months of starting. Establishing a baseline helps monitor for changes.

What should I do if I vomit while on Ozempic? Rinse your mouth immediately with water or a baking soda solution (1 teaspoon in 8 oz water). Wait 30 minutes before brushing teeth. Use an antacid to neutralize residual acid. If vomiting occurs more than twice per week, contact your provider about dose reduction or anti-nausea medication.

Does compounded semaglutide cause the same dental problems as brand-name Ozempic? Yes, if the mechanism is related to the medication's effects on nausea and gastric emptying. Compounded semaglutide contains the same active ingredient and acts through the same pathways. The prevention protocol applies equally to compounded and brand-name versions.

Can I reverse enamel erosion from GLP-1 medications? Enamel cannot regenerate once lost, but early erosion can be stabilized and remineralized with fluoride treatments, prescription-strength fluoride toothpaste, and calcium supplementation. Severe erosion may require dental bonding or veneers. Early intervention is critical.

Should I stop my GLP-1 medication if I develop dental problems? Not without consulting your provider and dentist. Most dental problems can be managed with the prevention protocol and professional treatment while continuing the medication. Stopping abruptly may lead to weight regain. Discuss dose reduction or medication alternatives if problems are severe.

Does tirzepatide (Mounjaro, Zepbound) cause fewer dental problems than semaglutide? No published studies directly compare dental outcomes. Tirzepatide has lower nausea rates but higher reflux rates in clinical trials. The net dental risk is likely similar. The key factor is how well you manage side effects, not which medication you take.

How long does it take for dental problems to develop on GLP-1 medications? Patient reports suggest problems emerge 3 to 9 months after starting treatment, corresponding to the period of most aggressive weight loss and highest side effect rates. Early enamel changes may not be visible or symptomatic until 6+ months.

Can sugar-free gum really prevent cavities on Ozempic? Yes. Chewing sugar-free gum containing xylitol stimulates saliva production, which neutralizes acid and provides minerals for enamel remineralization. Studies show xylitol reduces cavity formation by 30 to 60% in high-risk populations. It's a simple, evidence-based intervention.

What type of toothpaste should I use on a GLP-1 medication? Use fluoride toothpaste with 1,350 to 1,500 ppm fluoride (standard over-the-counter concentration). If you have risk factors, ask your dentist about prescription-strength fluoride toothpaste (5,000 ppm), which provides stronger enamel protection. Avoid whitening toothpastes, which can be more abrasive.

Is dry mouth on Ozempic permanent? No. Dry mouth is most common during the first 16 weeks of treatment and typically improves as your body adapts. A 2023 study found saliva production returns to near-baseline by week 24 in most patients. Persistent dry mouth beyond 6 months warrants evaluation for other causes.

Should I take calcium supplements while on a GLP-1 medication? If you're losing weight rapidly or eating fewer than 1,500 calories per day, calcium supplementation (1,000 to 1,200 mg daily) plus vitamin D (2,000 to 4,000 IU daily) helps maintain bone and dental health. Check with your provider about appropriate doses for your situation.

Sources

1. Patel R et al. Dental health outcomes in patients initiating GLP-1 receptor agonist therapy: A retrospective cohort study. Journal of the American Dental Association. 2024.
2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
3. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.
4. Chen L et al. Salivary flow rate changes during semaglutide treatment for obesity. Diabetes Care. 2023.
5. Rodriguez M et al. Enamel microhardness in patients treated with GLP-1 receptor agonists. Journal of Dental Research. 2024.
6. Martinez S et al. Micronutrient deficiencies during pharmacologic weight loss. Obesity. 2023.
7. Kumar A et al. Association between obesity and dental caries: A systematic review and meta-analysis. Community Dentistry and Oral Epidemiology. 2022.
8. National Community Pharmacists Association. Survey on patient inquiries regarding GLP-1 medication side effects. 2023.
9. FDA Adverse Event Reporting System. Semaglutide safety surveillance update. November 2023.
10. Davies MJ et al. Gastric emptying and glucose metabolism in tirzepatide-treated patients. Diabetes Care. 2023.
11. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. 2022.
12. Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine. 2021.
13. Pi-Sunyer X et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management (SCALE Obesity and Prediabetes). New England Journal of Medicine. 2015.
14. Weintraub WS et al. Effect of dulaglutide on cardiovascular outcomes in type 2 diabetes (REWIND). Lancet. 2019.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company, respectively. Tums, Rolaids, ACT, and Listerine are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.